Gene
CD69
CD69 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (35), Actionable biomarkers (1), Trial mentions (39), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention CD69. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 25 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 59 of 11,460 | 0.51% |
| 2022 | 2 of 8,285 | 0.02% | 75 of 13,598 | 0.55% |
| 2021 | 1 of 8,692 | 0.01% | 88 of 15,045 | 0.58% |
| 2020 | 1 of 7,640 | 0.01% | 72 of 14,459 | 0.50% |
| 2019 | 3 of 7,300 | 0.04% | 46 of 12,159 | 0.38% |
| 2018 | 1 of 6,927 | 0.01% | 46 of 11,854 | 0.39% |
| 2017 | 6 of 6,558 | 0.09% | 46 of 11,595 | 0.40% |
Showing 10 of 37 years.
Assay-provider ledger (35)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| NaMi Diagnostics | Diagnostic provider | Clinical validation | 1 | January 01, 2025 |
| ABCAM | Reagent supplier | Clinical validation | 1 | September 29, 2023 |
| PROTEINTECH | Reagent supplier | Clinical validation | 1 | September 29, 2023 |
| BD Bioscience | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | July 01, 2021 |
| Millipore | Reagent supplier | No clinical or analytical validation recorded for this pair | 1 | July 01, 2021 |
Showing 5 of 35 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| CD69 undexpression | Bendamustine | response-associated | chronic lymphocytic leukemia | Cancer Genome Interpreter |
Trial mentions (39)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01933594 | Trial outcomes (AACT) |
| NCT02440789 | Trial outcomes (AACT) |
| NCT02720107 | Trial outcomes (AACT) |
| NCT04793399 | Trial outcomes (AACT) |
| NCT02229084 | Trial outcomes (AACT) |
Showing 5 of 39 trial mentions.
Target-disease associations (317)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| AIDS | genetic, familial or congenital disease | Literature (Europe PMC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Andersen-Tawil syndrome | genetic, familial or congenital disease | Literature (Europe PMC) |
| Autoimmune Hepatitis | endocrine system disease | Literature (Europe PMC) |
| Autoimmune lymphoproliferative syndrome with recurrent viral infections | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 317 associations.
Vendor sourcing (68)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | CD69 | View trial NCT05283135 |
| Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Trial collaborator | Mentioned in trial textTrial free-text mention | CD69 | View trial NCT02411539 |
| Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Trial sponsor | Mentioned in trial textTrial free-text mention | CD69 | View trial NCT02440789 |
| Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Trial sponsor | Mentioned in trial textTrial free-text mention | CD69 | View trial NCT02155985 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.356C>T (p.T119I) alteration is located in exon 3 (coding exon 3) of the CD69 gene. This alteration results from a C to T substitution at nucleotide pos... | View ClinVar record SCV003594686.2 |
Showing 5 of 68 sourcing records.
Trial-cited literature (787)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Bacterial vaginosis associates with dysfunctional T cells and altered soluble immune factors in the cervicovaginal tract. | The Journal of clinical investigation | 2025 | 7 |
| A gold nanoparticle/peptide vaccine designed to induce SARS-CoV-2-specific CD8 T cells: a double-blind, randomized, phase 1 study in Switzerland. | BMC infectious diseases | 2025 | 6 |
| Unsupervised machine learning identifies distinct SLE patient endotypes with differential response to belimumab. | Rheumatology (Oxford, England) | 2025 | 5 |
| Durability of next-generation self-replicating RNA vaccine RBI-4000: a phase 1, randomized open label clinical trial. | Communications medicine | 2025 | 3 |
| Tumor microenvironment delineates differential responders to trastuzumab emtansine in HER2-positive metastatic breast cancer patients previously treated with pyrotinib: an exploratory biomarker analysis of a phase II study (NJMU-BC02). | Signal transduction and targeted therapy | 2025 | 2 |
Showing 5 of 787 papers.
Protein variant mentions (1)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.R32H | 1 | 2023 | PMID 36521103 |
Literature-extracted relations (61)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Aspirin | Chemical | negative_correlate |
Low-dose aspirin is not effective as an adjunct treatment for HIV infection among people living with HIV on dolutegravir-based antiretroviral therapy: A randomised double-blind, parallel-group placebo-controlled trial. | 2025 |
| Panobinostat | Chemical | negative_correlate |
Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients. | 2015 |
| Valacyclovir | Chemical | positive_correlate |
Valacyclovir therapy does not reverse herpes-associated alterations in cervical immunology: a randomized, placebo-controlled crossover trial. | 2014 |
| IPILIMUMAB | Chemical | positive_correlate |
Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. | 2014 |
| AXITINIB | Chemical | negative_correlate |
Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. | 2013 |
Showing 5 of 61 relation assertions.
Organizations publishing (512)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 51 | 1998 to 2023 |
| Dana-Farber Cancer Institute | Other | 20 | 2010 to 2024 |
| Mass General Brigham | Hospital | 18 | 2010 to 2024 |
| Harvard Medical School | Academic | 17 | 1997 to 2023 |
| University of London | Academic | 17 | 2002 to 2024 |
Showing 5 of 512 organizations.
Where CD69 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of ear
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- reproductive system or breast disease
- respiratory or thoracic disease
- urinary system disease
310 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.